SEC Form 4 · accession 0001209191-18-003056
Juno Therapeutics, Inc. · JUNO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Nelsen
Director
Period of report
Jan 5, 2018
Accepted (ET)
Jan 9, 2018 · 9:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001594864
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 5, 2018 | A | 237 | $0.00 | A | 54,058 | D | |
| Common StockF2 | holding | — | — | — | 10,552,390 | I | Held by ARCH Venture Fund VII, L.P. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Consists of fully vested restricted stock units.
- F2These shares are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"). The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"). The Reporting Person is a Managing Director of ARCH VII LLC and is deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by ARCH Fund VII. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.